Exenatide, a synthetic version of exendin-4, a GLP-1 receptor agonist, is widely used to treat diabetes and obesity and has the potential to be repurposed for the treatment of increased ICP (Fig. 1). Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.